Regenxbio Inc (NAS:RGNX)
$ 10 0.08 (0.81%) Market Cap: 495.45 Mil Enterprise Value: 320.09 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 65/100

Regenxbio Inc to Host Virtual Investor Day Transcript

Jul 11, 2023 / 12:30PM GMT
Release Date Price: $19.83 (+0.46%)
Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Welcome to our REGENXBIO Virtual Investor Day event. I am Ken Mills, CEO of REGENXBIO. I'm pleased to introduce our agenda and make some opening remarks. For this event, we have a program to provide an update on the company's pipeline with a focus on programs with expected interim clinical trial data to present in the second half of 2023.

Among other things today, we'll introduce some new interim safety data from our AAVIATE and ALTITUDE clinical trials, a new pipeline program for the treatment of Duchenne and some specific guidance about additional interim trial updates later this year. We're also pleased to be introduced by 3 external experts who are leaders in the fields of Duchenne research and retinal disease. Professor Dickson and Dr. Kaiser and Sheth will enjoy, engage with management in a discussion, each program review and participate in our live Q&A session at the end of the program. I'm grateful for George, Peter and Veeral to join us today.

(Operator Instructions) Today's event will include forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot